



Dysregulation of Host Cellular microRNA Expression by the Human Papillomavirus E6 and E7 Oncoproteins

Permanent link

<http://nrs.harvard.edu/urn-3:HUL.InstRepos:40046534>

Terms of Use

This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA>

Share Your Story

The Harvard community has made this article openly available.
Please share how this access benefits you. [Submit a story](#).

[Accessibility](#)

43	miR-221	hsa-miR-221-3p	agcuacauugucugcuggguuuc	YES	hepatocellular carcinoma, prostate cancer, NSCLC, ovarian cancer, gastric cancer	PMID: 24124720, PMID: 24583788, PMID: 22009180, PMID: 23569131, PMID: 22432036
44	miR-222	hsa-miR-222-3p	agcuacaucuggcuaucugggu	YES	acute lymphoblastic leukemia, ESCC (x2), hepatocellular carcinoma (x2), NSCLC (x3), gastric cancer, breast cancer	PMID: 23484694, PMID: 24651474, PMID: 22105822, PMID: 23342174, PMID: 22860003, PMID: 24390317, PMID: 24531034, PMID: 24595450, PMID: 24440980, PMID: 22009180
45	miR-223	hsa-miR-223-3p	ugucaguuugucaaaaucccca	YES	pancreatic cancer, breast cancer, ovarian cancer	PMID: 24578785, PMID: 24498016, PMID: 24366298
46	miR-25	hsa-miR-25-3p	cauugcacuugucucggucuga	YES	ESCC (x2), gastric cancer	PMID: 24651474, PMID: 24595006, PMID: 24390317
47	miR-26a	hsa-miR-26a-5p	uucaaguaauccaggauaggcu	YES	hepatocellular carcinoma, ovarian cancer (x2)	PMID: 22105822, PMID: 24466274, PMID: 23542579
48	miR-27a	hsa-miR-27a-3p	uucaagugggcuaguuccgc	YES	NSCLC, hepatocellular carcinoma, gastric cancer	PMID: 21544802, PMID: 22105822, PMID: 21112772
49	miR-29a	hsa-miR-29a-3p	uagcaccuucugaaaucgguaa	YES	colorectal cancer (x5), breast cancer, ovarian cancer	PMID: 19876917, PMID: 19201770, PMID: 24498016, PMID: 23673725, PMID: 23625654, PMID: 18954897, PMID: 23267864
50	miR-29b	hsa-miR-29b-3p	uagcaccuuugaaaucaguguu	YES	potential normalizer	
51	miR-29c	hsa-miR-29c-3p	uagcaccuuugaaaucgguaa	YES	NSCLC (x2), mesothelioma, colorectal cancer	PMID: 21544802, PMID: 22617246, PMID: 24523873, PMID: 23970420
52	miR-320a	hsa-miR-320a	aaaagcuggguugagaggcgga	YES	colon cancer	PMID: 24400111
53	miR-335	hsa-miR-335-5p	ucaagagcaauaacgaaaaaugu	YES	breast cancer, colorectal cancer	PMID: 20801493, PMID: 23267864
54	miR-34a	hsa-miR-34a-5p	uggcagugucuuagcugguugu	YES	multiple myeloma, DLBCL, breast cancer, colorectal cancer, gastric cancer	PMID: 21987025, PMID: 24241494, PMID: 23748853, PMID: 22648208, PMID: 21112772
55	miR-34b	hsa-miR-34b-3p	caaucacuaacuccacugccau	NO	osteosarcoma	PMID: 24063968
56	miR-375	hsa-miR-375	uuuguucguucggcucgcguga	YES	prostate cancer, ESCC (x2), pancreatic cancer (x2), NSCLC (x2), breast cancer	PMID: 22240788, PMID: 22519435, PMID: 23329235, PMID: 24390317, PMID: 24048453, PMID: 24404590, PMID: 24513341, PMID: 22952344
57	miR-376c	hsa-miR-376c-3p	aacauagaggaaauccacgu	NO	breast cancer (x2), gastric cancer	PMID: 24194846, PMID: 22927033, PMID: 22432036
58	miR-378	hsa-miR-378a-3p	acuggacuuggagucagaaggc	NO	colorectal cancer, gastric cancer	PMID: 24423916, PMID: 22432036
59	miR-409	hsa-miR-409-3p	gaauguugcucggugaaccccu	YES	breast cancer (x2)	PMID: 24194846, PMID: 22927033
60	miR-451	hsa-miR-451a	aaaccguuaccuuacugaguu	YES	potential hemolysis marker, colon cancer, breast cancer, gastric cancer (x2)	PMID: 24400111, PMID: 23301032, PMID: 24595006, PMID: 22262318
61	miR-483-5p	hsa-miR-483-5p	aagacgggaggaaagaaggag	NO	ESCC, breast cancer, ovarian cancer	PMID: 24651474, PMID: 21060830, PMID: 24223734
62	miR-486	hsa-miR-486-5p	uccuguacugagcugccccgag	YES	potential hemolysis marker, NSCLC, gastric cancer (x2), lung cancer, breast cancer	PMID: 21116241, PMID: 24595006, PMID: 21864403, PMID: 22262318, PMID: 24498016
63	miR-574	hsa-miR-574-3p	cacgcucaugcacacaccaca	YES	prostate cancer, NSCLC, breast cancer	PMID: 22240788, PMID: 21258252, PMID: 21060830
64	miR-625-3p	hsa-miR-625-3p	gacuaauagaacuuccccuca	NO	mesothelioma, lung cancer	PMID: 22617246, PMID: 22675530
65	miR-652	hsa-miR-652-3p	aauggcgccacuaggguuugug	YES	breast cancer (x2), colorectal cancer	PMID: 24194846, PMID: 24498016, PMID: 24022433
66	miR-9	hsa-miR-9-5p	ucuuugguuauacuagcuguauga	YES	endometrial carcinoma	PMID: 22987275
67	miR-92a	hsa-miR-92a-3p	uauugcacuugucccgccugu	NO	non-Hodgkin lymphoma, leukemia (x2), gastric cancer, colorectal cancer (x4), mesothelioma, endometrial carcinoma, ovarian cancer (x3)	PMID: 21383985, PMID: 19440243, PMID: 21182798, PMID: 24595006, PMID: 19876917, PMID: 22617246, PMID: 22987275, PMID: 22648208, PMID: 23673725, PMID: 23625654, PMID: 18954897, PMID: 23963852, PMID: 24366298

68	miR-93-5p	hsa-mir-93-5p	caaagugcuguucgugcagguag	YES	acute myeloid leukemia, NSCLC, breast cancer (x2), ovarian cancer	PMID: 23437222, PMID: 24523873, PMID: 24498016, PMID: 23748853, PMID: 18954897
69	x-control	x-control	x-control	N/A	internal reference	
70	blank	blank	none	N/A	internal reference	

References

PMID:

- 18318758 Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. *Br J Haematol*. 2008;141(5):672-675.
- 18348159 Wang M, Tan LP, Dijkstra MK, et al. miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. *J Pathol*. 2008;215(1):13-20.
- 18954897 Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM, Cohn DE. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. *Gynecol Oncol*. 2009;112(1):55-59.
- 19201770 Ng EK, Chong WW, Jin H, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. *Gut*. 2009;58(10):1375-1381.
- 19440243 Tanaka M, Oikawa K, Takanashi M, et al. Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. *PLoS One*. 2009;4(5):e5532.
- 19723895 Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. *Cancer Prev Res (Phila)*. 2009;2(9):807-813.
- 19876917 Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *Int J Cancer*. 2010;127(1):118-126.
- 20234369 Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. *Br J Cancer*. 2010;102(7):1174-1179.
- 20801493 Wang F, Zheng Z, Guo J, Ding X. Correlation and quantitation of microRNA aberrant expression in tissues and sera from patients with breast tumor. *Gynecol Oncol*. 2010;119(3):586-593.
- 21060830 Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. *PLoS One*. 2010;5(10):e13735.
- 21112772 Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. *Eur J Cancer*. 2011;47(5):784-791.
- 21116241 Shen J, Todd NW, Zhang H, et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. *Lab Invest*. 2011;91(4):579-587.
- 21139804 Ali S, Almhanna K, Chen W, Philip PA, Sarkar FH. Differentially expressed miRNAs in the plasma may provide a molecular signature for aggressive pancreatic cancer. *Am J Transl Res*. 2010;3(1):28-47.
- 21182798 Ohyashiki JH, Umezu T, Kobayashi C, et al. Impact on cell to plasma ratio of miR-92a in patients with acute leukemia: in vivo assessment of cell to plasma ratio of miR-92a. *BMC Res Notes*. 2010;3:347.
- 21206010 Guo HQ, Huang GL, Guo CC, Pu XX, Lin TY. Diagnostic and prognostic value of circulating miR-221 for extranodal natural killer/T-cell lymphoma. *Dis Markers*. 2010;29(5):251-258.
- 21258252 Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ. miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early-stage non-small cell lung cancer. *J Thorac Oncol*. 2011;6(3):482-488.
- 21278583 Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. *J Clin Gastroenterol*. 2011;45(4):355-360.

- 21383985 Ohyashiki K, Umezumi T, Yoshizawa S, et al. Clinical impact of down-regulated plasma miR-92a levels in non-Hodgkin's lymphoma. *PLoS One*. 2011;6(2):e16408.
- 21398193 Roth C, Kasimir-Bauer S, Pantel K, Schwarzenbach H. Screening for circulating nucleic acids and caspase activity in the peripheral blood as potential diagnostic tools in lung cancer. *Mol Oncol*. 2011;5(3):281-291.
- 21445232 Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. *PLoS One*. 2011;6(3):e17745.
- 21544802 Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC. Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. *Int J Cancer*. 2012;130(6):1378-1386.
- 21602271 Stagakis E, Bertias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. *Ann Rheum Dis*. 2011;70(8):1496-1506.
- 21627863 Wei J, Gao W, Zhu CJ, et al. Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. *Chin J Cancer*. 2011;30(6):407-414.
- 21721011 Wang ZX, Bian HB, Wang JR, Cheng ZX, Wang KM, De W. Prognostic significance of serum miRNA-21 expression in human non-small cell lung cancer. *J Surg Oncol*. 2011;104(7):847-851.
- 21749846 Tomimaru Y, Eguchi H, Nagano H, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. *J Hepatol*. 2012;56(1):167-175.
- 21864403 Shen J, Liu Z, Todd NW, et al. Diagnosis of lung cancer in individuals with solitary pulmonary nodules by plasma microRNA biomarkers. *BMC Cancer*. 2011;11:374.
- 21904633 Zheng D, Haddadin S, Wang Y, et al. Plasma microRNAs as novel biomarkers for early detection of lung cancer. *Int J Clin Exp Pathol*. 2011;4(6):575-586.
- 21920043 Zhu W, Liu X, He J, Chen D, Hunag Y, Zhang YK. Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. *BMC Cancer*. 2011;11:393.
- 21987025 Fang C, Zhu DX, Dong HJ, et al. Serum microRNAs are promising novel biomarkers for diffuse large B cell lymphoma. *Ann Hematol*. 2012;91(4):553-559.
- 22009180 Lin Q, Mao W, Shu Y, et al. A cluster of specified microRNAs in peripheral blood as biomarkers for metastatic non-small-cell lung cancer by stem-loop RT-PCR. *J Cancer Res Clin Oncol*. 2012;138(1):85-93.
- 22045190 Morimura R, Komatsu S, Ichikawa D, et al. Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. *Br J Cancer*. 2011;105(11):1733-1740.
- 22105822 Zhou J, Yu L, Gao X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. *J Clin Oncol*. 2011;29(36):4781-4788.
- 22156446 Zhao R, Wu J, Jia W, et al. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. *Onkologie*. 2011;34(12):675-680.
- 22240788 Bryant RJ, Pawlowski T, Catto JW, et al. Changes in circulating microRNA levels associated with prostate cancer. *Br J Cancer*. 2012;106(4):768-774.
- 22262318 Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre- and post-operative plasma. *Br J Cancer*. 2012;106(4):740-747.
- 22298119 Shen J, Hruby GW, McKiernan JM, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. *Prostate*. 2012;72(13):1469-1477.

- 22389695 Hennessey PT, Sanford T, Choudhary A, et al. Serum microRNA biomarkers for detection of non-small cell lung cancer. *PLoS One*. 2012;7(2):e32307.
- 22406928 Wang M, Gu H, Wang S, et al. Circulating miR-17-5p and miR-20a: molecular markers for gastric cancer. *Mol Med Rep*. 2012;5(6):1514-1520.
- 22432036 Song MY, Pan KF, Su HJ, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. *PLoS One*. 2012;7(3):e33608.
- 22519435 Komatsu S, Ichikawa D, Takeshita H, et al. Prognostic impact of circulating miR-21 and miR-375 in plasma of patients with esophageal squamous cell carcinoma. *Expert Opin Biol Ther*. 2012;12 Suppl 1:S53-59.
- 22541087 Ge TT, Liang Y, Fu R, et al. [Expressions of miR-21, miR-155 and miR-210 in plasma of patients with lymphoma and its clinical significance]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2012;20(2):305-309.
- 22617246 Kirschner MB, Cheng YY, Badrian B, et al. Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. *J Thorac Oncol*. 2012;7(7):1184-1191.
- 22638884 Wang B, Zhang Q. The expression and clinical significance of circulating microRNA-21 in serum of five solid tumors. *J Cancer Res Clin Oncol*. 2012;138(10):1659-1666.
- 22648208 Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. *J Surg Oncol*. 2012;106(8):947-952.
- 22675530 Roth C, Stückrath I, Pantel K, Izbicki JR, Tachezy M, Schwarzenbach H. Low levels of cell-free circulating miR-361-3p and miR-625* as blood-based markers for discriminating malignant from benign lung tumors. *PLoS One*. 2012;7(6):e38248.
- 22692639 Guo LJ, Zhang QY. Decreased serum miR-181a is a potential new tool for breast cancer screening. *Int J Mol Med*. 2012;30(3):680-686.
- 22806310 Yuxia M, Zhennan T, Wei Z. Circulating miR-125b is a novel biomarker for screening non-small-cell lung cancer and predicts poor prognosis. *J Cancer Res Clin Oncol*. 2012;138(12):2045-2050.
- 22860003 Li BS, Zhao YL, Guo G, et al. Plasma microRNAs, miR-223, miR-21 and miR-218, as novel potential biomarkers for gastric cancer detection. *PLoS One*. 2012;7(7):e41629.
- 22868372 Kanaan Z, Rai SN, Eichenberger MR, et al. Plasma miR-21: a potential diagnostic marker of colorectal cancer. *Ann Surg*. 2012;256(3):544-551.
- 22891887 Liu R, Liao J, Yang M, et al. Circulating miR-155 expression in plasma: a potential biomarker for early diagnosis of esophageal cancer in humans. *J Toxicol Environ Health A*. 2012;75(18):1154-1162.
- 22927033 Cuk K, Zucknick M, Heil J, et al. Circulating microRNAs in plasma as early detection markers for breast cancer. *Int J Cancer*. 2013;132(7):1602-1612.
- 22952344 Madhavan D, Zucknick M, Wallwiener M, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. *Clin Cancer Res*. 2012;18(21):5972-5982.
- 22954417 Valladares-Ayerbes M, Reboredo M, Medina-Villaamil V, et al. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer. *J Transl Med*. 2012;10:186.
- 22956063 Li C, Li JF, Cai Q, et al. miRNA-199a-3p in plasma as a potential diagnostic biomarker for gastric cancer. *Ann Surg Oncol*. 2013;20 Suppl 3:S397-405.
- 22983388 Cui EH, Li HJ, Hua F, et al. Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy. *Acta Pharmacol Sin*. 2013;34(2):309-313.

- 22987275 Torres A, Torres K, Pesci A, et al. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients. *Int J Cancer*. 2013;132(7):1633-1645.
- 23212612 Gorur A, Balci Fidanci S, Dogruer Unal N, et al. Determination of plasma microRNA for early detection of gastric cancer. *Mol Biol Rep*. 2013;40(3):2091-2096.
- 23263848 Chen Q, Si Q, Xiao S, et al. Prognostic significance of serum miR-17-5p in lung cancer. *Med Oncol*. 2013;30(1):353.
- 23267156 Komatsu S, Ichikawa D, Tsujiura M, et al. Prognostic impact of circulating miR-21 in the plasma of patients with gastric carcinoma. *Anticancer Res*. 2013;33(1):271-276.
- 23267864 Giráldez MD, Lozano JJ, Ramírez G, et al. Circulating microRNAs as biomarkers of colorectal cancer: results from a genome-wide profiling and validation study. *Clin Gastroenterol Hepatol*. 2013;11(6):681-688.e683.
- 23269581 Ouyang L, Liu P, Yang S, Ye S, Xu W, Liu X. A three-plasma miRNA signature serves as novel biomarkers for osteosarcoma. *Med Oncol*. 2013;30(1):340.
- 23301032 Ng EK, Li R, Shin VY, et al. Circulating microRNAs as specific biomarkers for breast cancer detection. *PLoS One*. 2013;8(1):e53141.
- 23307259 Cai H, Yuan Y, Hao YF, Guo TK, Wei X, Zhang YM. Plasma microRNAs serve as novel potential biomarkers for early detection of gastric cancer. *Med Oncol*. 2013;30(1):452.
- 23329235 Kawaguchi T, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. *Br J Cancer*. 2013;108(2):361-369.
- 23342174 Sanfiorenzo C, Ilie MI, Belaid A, et al. Two panels of plasma microRNAs as non-invasive biomarkers for prediction of recurrence in resectable NSCLC. *PLoS One*. 2013;8(1):e54596.
- 23372341 Liu J, Mao Q, Liu Y, Hao X, Zhang S, Zhang J. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. *Chin J Cancer Res*. 2013;25(1):46-54.
- 23377530 Zhang HL, Qin XJ, Cao DL, et al. An elevated serum miR-141 level in patients with bone-metastatic prostate cancer is correlated with more bone lesions. *Asian J Androl*. 2013;15(2):231-235.
- 23391324 Fayyad-Kazan H, Bitar N, Najjar M, et al. Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. *J Transl Med*. 2013;11:31.
- 23437222 Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia. *PLoS One*. 2013;8(2):e56718.
- 23484694 Lu XJ, Jiang Q, Huang PL, et al. [Preliminary analysis of aberrant expression of plasma miR-223 in pediatric acute lymphoblastic leukemia with a direct RT-PCR assay]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*. 2013;21(1):68-72.
- 23542579 Chung YW, Bae HS, Song JY, et al. Detection of microRNA as novel biomarkers of epithelial ovarian cancer from the serum of ovarian cancer patients. *Int J Gynecol Cancer*. 2013;23(4):673-679.
- 23569131 Hong F, Li Y, Xu Y, Zhu L. Prognostic significance of serum microRNA-221 expression in human epithelial ovarian cancer. *J Int Med Res*. 2013;41(1):64-71.
- 23579215 Hirajima S, Komatsu S, Ichikawa D, et al. Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma. *Br J Cancer*. 2013;108(9):1822-1829.
- 23625654 Liu GH, Zhou ZG, Chen R, et al. Serum miR-21 and miR-92a as biomarkers in the diagnosis and prognosis of colorectal cancer. *Tumour Biol*. 2013;34(4):2175-2181.

- 23673725 Brunet Vega A, Pericay C, Moya I, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. *Oncol Rep.* 2013;30(1):320-326.
- 23733518 Li C, Li JF, Cai Q, et al. MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. *J Surg Oncol.* 2013;108(2):89-92.
- 23748853 Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K, Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. *Clin Chem.* 2013;59(10):1489-1496.
- 23756108 Markou A, Sourvinou I, Vorkas PA, Yousef GM, Lianidou E. Clinical evaluation of microRNA expression profiling in non small cell lung cancer. *Lung Cancer.* 2013;81(3):388-396.
- 23774211 Wang Y, Gu J, Roth JA, et al. Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer. *Cancer Res.* 2013;73(15):4801-4809.
- 23797906 Chan M, Liaw CS, Ji SM, et al. Identification of circulating microRNA signatures for breast cancer detection. *Clin Cancer Res.* 2013;19(16):4477-4487.
- 23821659 Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood.* 2013;122(11):1891-1899.
- 23898484 Kumar S, Keerthana R, Pazhanimuthu A, Perumal P. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. *Indian J Biochem Biophys.* 2013;50(3):210-214.
- 23916610 Zhao J, Lei T, Xu C, et al. MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration through targeting B7-H3. *Biochem Biophys Res Commun.* 2013;438(2):439-444.
- 23963852 Guo F, Tian J, Lin Y, Jin Y, Wang L, Cui M. Serum microRNA-92 expression in patients with ovarian epithelial carcinoma. *J Int Med Res.* 2013;41(5):1456-1461.
- 23970420 Menéndez P, Padilla D, Villarejo P, et al. Prognostic implications of serum microRNA-21 in colorectal cancer. *J Surg Oncol.* 2013;108(6):369-373.
- 24022433 Kanaan Z, Roberts H, Eichenberger MR, et al. A plasma microRNA panel for detection of colorectal adenomas: a step toward more precise screening for colorectal cancer. *Ann Surg.* 2013;258(3):400-408.
- 24048453 Carlsen AL, Joergensen MT, Knudsen S, de Muckadell OB, Heegaard NH. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls. *Pancreas.* 2013;42(7):1107-1113.
- 24063968 Tian Q, Jia J, Ling S, Liu Y, Yang S, Shao Z. A causal role for circulating miR-34b in osteosarcoma. *Eur J Surg Oncol.* 2014;40(1):67-72.
- 24124720 Zhan MX, Li Y, Hu BS, et al. [Expression of serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular carcinoma and its clinical significance]. *Zhonghua Yi Xue Za Zhi.* 2013;93(23):1830-1832.
- 24157791 Wu H, Xiao Z, Wang K, Liu W, Hao Q. MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1. *Biochem Biophys Res Commun.* 2013;441(4):693-700.
- 24161319 Roncarati R, Viviani Anselmi C, Losi MA, et al. Circulating miR-29a, Among Other Up-Regulated MicroRNAs, Is the Only Biomarker for Both Hypertrophy and Fibrosis in Patients With Hypertrophic Cardiomyopathy. *J Am Coll Cardiol.* 2014;63(9):920-927.
- 24194846 Cuk K, Zucknick M, Madhavan D, et al. Plasma microRNA panel for minimally invasive detection of breast cancer. *PLoS One.* 2013;8(10):e76729.
- 24212760 Iwamoto H, Kanda Y, Sejima T, Osaki M, Okada F, Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. *Int J Oncol.* 2014;44(1):53-58.

- 24222179 Jones K, Nourse JP, Keane C, Bhatnagar A, Gandhi MK. Plasma microRNA are disease response biomarkers in classical Hodgkin lymphoma. *Clin Cancer Res.* 2014;20(1):253-264.
- 24223734 Zheng H, Zhang L, Zhao Y, et al. Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer. *PLoS One.* 2013;8(11):e77853.
- 24241494 Kubiczкова L, Kryukov F, Slaby O, et al. Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance. *Haematologica.* 2014;99(3):511-518.
- 24260062 Wang PY, Gong HT, Li BF, et al. Higher expression of circulating miR-182 as a novel biomarker for breast cancer. *Oncol Lett.* 2013;6(6):1681-1686.
- 24282590 Zhang H, Su Y, Xu F, Kong J, Yu H, Qian B. Circulating microRNAs in relation to EGFR status and survival of lung adenocarcinoma in female non-smokers. *PLoS One.* 2013;8(11):e81408.
- 24304648 Zhang J, Zhang K, Bi M, Jiao X, Zhang D, Dong Q. Circulating microRNA expressions in colorectal cancer as predictors of response to chemotherapy. *Anticancer Drugs.* 2014;25(3):346-352.
- 24310813 Chen J, Wang W, Zhang Y, Chen Y, Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. *Med Oncol.* 2014;31(1):799.
- 24366298 Shapira I, Oswald M, Lovecchio J, et al. Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. *Br J Cancer.* 2014;110(4):976-983.
- 24390317 Wu C, Li M, Hu C, Duan H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. *Mol Biol Rep.* 2014;41(3):1257-1266.
- 24400111 Shivapurkar N, Weiner LM, Marshall JL, et al. Recurrence of early stage colon cancer predicted by expression pattern of circulating microRNAs. *PLoS One.* 2014;9(1):e84686.
- 24400911 Chen W, Wang H, Chen H, et al. Clinical significance and detection of microRNA-21 in serum of patients with diffuse large B-cell lymphoma in Chinese population. *Eur J Haematol.* 2014.
- 24404590 Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: a potential biomarker for patients with non-small-cell lung cancer. *Gene.* 2014;534(1):60-65.
- 24416156 Anfossi S, Giordano A, Gao H, et al. High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. *PLoS One.* 2014;9(1):e83113.
- 24423916 Zanutto S, Pizzamiglio S, Ghilotti M, et al. Circulating miR-378 in plasma: a reliable, haemolysis-independent biomarker for colorectal cancer. *Br J Cancer.* 2014;110(4):1001-1007.
- 24440980 Lv M, Zhu X, Chen W, Zhao J, Tang J. Searching for candidate microRNA biomarkers in detection of breast cancer: a meta-analysis. *Cancer Biomark.* 2013;13(5):395-401.
- 24466274 Shen W, Song M, Liu J, et al. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. *PLoS One.* 2014;9(1):e86871.
- 24481716 Chen Q, Ge X, Zhang Y, et al. Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. *Oncol Rep.* 2014;31(4):1863-1870.
- 24498016 McDermott AM, Miller N, Wall D, et al. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. *PLoS One.* 2014;9(1):e87032.
- 24513341 Yu H, Jiang L, Sun C, et al. Decreased circulating miR-375: A potential biomarker for patients with non-small-cell lung cancer. *Gene.* 2013.

- 24523873 Zhu W, He J, Chen D, et al. Expression of miR-29c, miR-93, and miR-429 as potential biomarkers for detection of early stage non-small lung cancer. *PLoS One*. 2014;9(2):e87780.
- 24531034 Wu C, Cao Y, He Z, et al. Serum levels of miR-19b and miR-146a as prognostic biomarkers for non-small cell lung cancer. *Tohoku J Exp Med*. 2014;232(2):85-95.
- 24578785 Ganepola GA, Rutledge JR, Suman P, Yiengpruksawan A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. *World J Gastrointest Oncol*. 2014;6(1):22-33.
- 24583788 Singh PK, Preus L, Hu Q, et al. Serum microRNA expression patterns that predict early treatment failure in prostate cancer patients. *Oncotarget*. 2014;5(3):824-840.
- 24595006 Zhu C, Ren C, Han J, et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. *Br J Cancer*. 2014.
- 24595450 Giray BG, Emekdas G, Tezcan S, et al. Profiles of serum microRNAs; miR-125b-5p and miR223-3p serve as novel biomarkers for HBV-positive hepatocellular carcinoma. *Mol Biol Rep*. 2014.
- 24600991 Zhu YJ, Xu B, Xia W. Hsa-mir-182 downregulates RASA1 and suppresses lung squamous cell carcinoma cell proliferation. *Clin Lab*. 2014;60(1):155-159.
- 24626859 Tsujiura M, Komatsu S, Ichikawa D, et al. Circulating miR-18a in plasma contributes to cancer detection and monitoring in patients with gastric cancer. *Gastric Cancer*. 2014.
- 24646542 Frampton AE, Krell J, Gall TM, Castellano L, Stebbing J, Jiao LR. miR-15b and miR-17 Are Tumor-Derived Plasma MicroRNAs Dysregulated in Colorectal Neoplasia. *Ann Surg*. 2014.
- 24649179 Zhang GJ, Zhou T, Liu ZL, Tian HP, Xia SS. Plasma miR-200c and miR-18a as potential biomarkers for the detection of colorectal carcinoma. *Mol Clin Oncol*. 2013;1(2):379-384.
- 24651474 Wu C, Wang C, Guan X, et al. Diagnostic and Prognostic Implications of a Serum miRNA Panel in Oesophageal Squamous Cell Carcinoma. *PLoS One*. 2014;9(3):e92292.
- 24661838 Medina-Villaamil V, Martínez-Breijo S, Portela-Pereira P, et al. Circulating MicroRNAs in Blood of Patients With Prostate Cancer. *Actas Urol Esp*. 2014.
- 24664585 Yang Y, Qian J, Chen Y, Pan Y. Prognostic role of circulating microRNA-21 in cancers: evidence from a meta-analysis. *Tumour Biol*. 2014.